Global News

Paying attention to rare disease markets

Tuesday, September 5, 2017

The Pulse on Global Trials by Matthew Howes

The market opportunity of rare diseases is tremendous. Experts predict global sales of drugs with orphan designations will reach $176 billion by 2020. Biopharma as an industry is collectively investigating some 450 different orphan drugs, demonstrating the strategic value inherent in the category. But with over 6,000 rare diseases affecting an estimated 350 million people around the world, they have only just begun to tap the full market potential.

[Read More]

Jesper Ericsson appointed new CEO of Symcel

Friday, September 1, 2017

Symcel has announced that Jesper Ericsson has joined Symcel as Chief Executive Officer—with the appointment effective immediately. Ericsson was formally Director of Marketing and Sales at BioLamina, where he was responsible for direct sales both internationally and at a global and regional distributor level. During the past 10 years, Jesper has gained broad experience of the commercialization of research-based products through his work at the Unit for Bioentrepreneurship at the Karolinska Institute, Stockholm School of Entrepreneurship and as co-founder of the Stockholm BiotechBuilders Association. He holds a Ph.D. in neuroscience from the Karolinska Institute and a MSc in medical technology from the Royal Institute of Technology in Stockholm.

[Read More]

Science Exchange signs on as LabCentral sponsor

Wednesday, August 30, 2017

Biotech innovation hub LabCentral has signed Science Exchange, a secure platform for outsourced research and development (R&D), as a sponsor to support its life science and biotech resident startups. Companies within LabCentral’s shared workspaces are now able to order R&D services instantly via a customized Science Exchanged-powered marketplace, with access to more than 2,500 qualified scientific service providers.

[Read More]

LifeArc, AUTM partner on training for scholars in technology transfer

Wednesday, August 30, 2017

LifeArc, the medical research charity formerly known as MRC Technology, has partnered with The Association of University Technology Managers (AUTM) Foundation to offer a competitive program that will provide essential training for scientists seeking a career in life sciences technology transfer. This joint initiative emphasizes the commitment of both organizations to improve access to the technology transfer profession.

[Read More]

Parcom Capital acquires Viroclinics Biosciences

Wednesday, August 30, 2017

Viroclinics, founded in 2001 and specializing in testing new vaccines and drugs in the clinical trial stages prior to their market launch, has been acquired by Parcom Capital. Viroclinics has clients across the globe and conducts virology testing for clients that include the world’s top 10 biopharmaceutical companies. The company is also a market leader in the Netherlands. For instance, Viroclinics tests around 90 percent of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.

[Read More]

LabCorp names Dr. Brian Caveney as enterprise-wide chief medical officer

Tuesday, August 29, 2017

LabCorp, a global life sciences company, announced that Dr. Brian Caveney, a nationally recognized health-policy expert who currently serves as chief medical officer of Blue Cross and Blue Shield of North Carolina (Blue Cross NC), will fill a newly created role as enterprise-wide chief medical officer of LabCorp, effective Sept. 25. Caveney will report to David P. King, chairman and CEO of LabCorp.

[Read More]